Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma

BACKGROUND: Recently, maintaining higher relative dose intensity (RDI) of chemotherapeutic drugs has become a widespread practice in an attempt to achieve better outcomes in the treatment of aggressive lymphoma. The addition of rituximab to chemotherapy regimens has significantly improved outcome in...

Descripción completa

Detalles Bibliográficos
Autores principales: Terada, Yoshiki, Nakamae, Hirohisa, Aimoto, Ran, Kanashima, Hiroshi, Sakamoto, Erina, Aimoto, Mizuki, Inoue, Eri, Koh, Hideo, Nakane, Takahiko, Takeoka, Yasunobu, Ohsawa, Masahiko, Koh, Ki-Ryang, Yamane, Takahisa, Nakao, Yoshitaka, Ohta, Kensuke, Mugitani, Atsuko, Teshima, Hirofumi, Hino, Masayuki
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743657/
https://www.ncbi.nlm.nih.gov/pubmed/19689822
http://dx.doi.org/10.1186/1756-9966-28-116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743657/
https://www.ncbi.nlm.nih.gov/pubmed/19689822
http://dx.doi.org/10.1186/1756-9966-28-116

Ejemplares similares